Data on double checkpoint targeting bsAbs in PCa are currently sparse, but constructs that simultaneously interfere with the PD-1 and LAG-3 or CTLA-4 axes have demonstrated activity in preclinical models 141; consistently, a PD-1/CTLA-4 bsAb performed well in a Phase I trial that included mCRPC patients 142. Here, CTLA4 is linked to posterior cortical atrophy.